Insider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 32,451 Shares of Stock

Vor Biopharma Inc. (NYSE:VOR) major shareholder Reprogrammed Interchange Llc sold 32,451 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $39.83, for a total transaction of $1,292,523.33. Following the transaction, the insider directly owned 1,605,209 shares of the company’s stock, valued at $63,935,474.47. This represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The stock was sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The shares were sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The shares were sold at an average price of $40.00, for a total transaction of $898,440.00.

Vor Biopharma Trading Up 2.1%

NYSE:VOR opened at $37.46 on Friday. Vor Biopharma Inc. has a 1-year low of $2.62 and a 1-year high of $65.80. The firm has a fifty day simple moving average of $38.88 and a 200 day simple moving average of $24.15. The stock has a market capitalization of $256.75 million, a PE ratio of -22.70 and a beta of 2.05.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on VOR shares. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Vor Biopharma in a research note on Thursday, August 14th. Stifel Nicolaus raised Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a report on Wednesday, September 24th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $113.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in Vor Biopharma in the second quarter valued at about $66,000. Money Concepts Capital Corp raised its stake in Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after acquiring an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in Vor Biopharma during the first quarter worth about $100,000. Finally, Two Sigma Investments LP raised its stake in Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after acquiring an additional 25,930 shares in the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.